DOCSLIB.ORG

Propoflo Dose with Propofol, May Be Required to Complete the Transition to Discarded Within 6 Hours

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Propoflo Dose with Propofol, May Be Required to Complete the Transition to Discarded Within 6 Hours For Animal Use Only halothane and isoflurane. No pharmacological incompatibility Induction Dosage Guidelines B. Maintenance by Inhalant Anesthetics: Once propofol has been opened, vial contents should be 10. Concurrent medication: No significant adverse preanesthetic regimens in dogs. JAVMA. 202:1111-1115 has been observed. Preanesthetic Propofol Propofol Rate of Administration Due to the rapid metabolism of propofol, additional low drawn into sterile syringes; each syringe should be prepared interactions with commonly used drugs have been observed. (1993). TM Induction doses of propofol, similar to those used for maintenance for single patient use only. Unused product should be 3. Plumb, D.C. ed. Veterinary Drug Handbook, Second Edition. INDICATIONS: 11. Perivascular administration: Perivascular administration PropoFlo Dose with propofol, may be required to complete the transition to discarded within 6 hours. Iowa State University Press, Ames, IA (1995). Propofol is an intravenous anesthetic injection for use in does not produce local tissue reaction. (propofol injectable emulsion) mg/kg Seconds mg/kg/min mL/kg/min inhalant maintenance anesthesia. Clinical trials using propofol 4. Detailed information on the preanesthetic doses used dogs as follows: 2. Anesthesia effects: Careful monitoring of the patient is None 5.5 40 - 60 5.5 - 8.3 0.55 - 0.83 have shown that it may be necessary to use a higher initial CONTRAINDICATIONS: with propofol in clinical studies is available in the Freedom of Intravenous Anesthetic Injection for 1. For induction of anesthesia. necessary when using propofol as a maintenance anesthetic Acepromazine 3.7 30 - 50 4.4 -7.4 0.44 - 0.74 concentration of the inhalant anesthetic halothane than Propofol injection is contraindicated in dogs with a known Information (FOI) Summary or can be obtained from Zoetis 2. For maintenance of general anesthesia for up to due to the possibility of rapid arousal. Apnea may occur Use in Dogs. Acepromazine / 2.6 30 - 50 3.1 - 5.2 0.31 - 0.52 is usually required following induction using barbiturate hypersensitivity to propofol or its components, or when Inc. 20 minutes. following maintenance doses of propofol. Oxymorphone anesthetics, due to rapid recovery from propofol5. general anesthesia or sedation are contraindicated. 5. Muir, W.W., J.A.E. Hubbell, R.T. Skarda, and R.M. Bednarski. Fliptop vial. Each mL contains 10 mg propofol. 3. For induction of general anesthesia where maintenance Following induction, additional propofol may be needed to Handbook of Veterinary Medicine, Second Edition. Mosby- Propofol doses and rates for the above premedicants were HUMAN USER SAFETY: Shake Well Before Use. is provided by inhalant anesthetics. OVERDOSAGE: complete the transition to inhalant maintenance anesthesia Year Book, Inc. (1995). based upon the following average dosages. These doses may Rapid administration or accidental overdosage of propofol due to rapid recovery from propofol. Doses administered Not for human use. Keep out of the reach of children. 6. Kamibayashi, T., Y. Hayashi, K. Sumikawa, A. Yamatodani, CAUTION: DOSAGE AND ADMINISTRATION: be lower than the label directions for their use as a single may cause cardiopulmonary depression. Respiratory arrest during the transition to inhalant anesthesia may result in Rare cases of self-administration have been reported, including K. Kawabata and I. Yoshiya. Enhancement by propofol of Federal (USA) law restricts this drug to use by or on the order Shake the vial thoroughly before opening. 3,4 medication . apnea. fatalities. Propofol should be managed to prevent the risk of of a licensed veterinarian. (apnea) may be observed. In cases of respiratory depression, epinephrine-induced arrhythmias in dogs. Anesthesiology Parenteral drug products should be inspected visually for Dose (mg/kg) Routes stop drug administration, establish a patent airway, and Propofol has also been used during inhalant maintenance diversion, through such measures as restriction of access and the 75:1035-1040 (1991). DESCRIPTION: particulate matter and discoloration prior to administration, Acepromazine 0.060 IM, SC, IV initiate assisted or controlled ventilation with pure oxygen. anesthesia to increase anesthetic depth. Propofol used use of drug accountability procedures appropriate to the clinical 7. Laxenaire, M.C., E. Mata-Bermejo, D.A. Moneret-Vautrin PropoFlo™ Injection is a sterile, nonpyrogenic emulsion whenever solution and container permit. Propofol is a white Oxymorphone 0.090 IM, SC, IV Cardiovascular depression should be treated with plasma during inhalant maintenance may result in apnea. setting. and J.L. Gueant. Life-threatening anaphylactoid reactions to containing 10 mg/mL of propofol suitable for intravenous stable emulsion; do not use if there is evidence of separation propofol (Diprivan®). Anesthesiology 77:275-280 (1992). Xylazine 0.33 IM, SC expanders, pressor agents, antiarrhythmic agents or other 3. Physiological effects: Mild hypotension may occur during Exercise caution to avoid accidental self-injection. Overdose administration. Propofol is chemically described as 2, of the phases. Do not use if there is evidence of excessive The use of these drugs as preanesthetics markedly reduces techniques as appropriate for the observed abnormality. propofol anesthesia. is likely to cause cardiorespiratory depression (such as Approved by FDA under NADA # 141-098 6-diisopropylphenol and has a molecular weight of 178.27. creaming or aggregation, if large droplets are visible, or if hypotension, bradycardia and/ or apnea). Remove the Propofol is very slightly soluble in water and is therefore propofol requirements. As with other sedative hypnotic agents, WARNINGS: 4. Premedicants: Premedicants may increase the anesthesia there are other forms of phase separation indicating that individual from the source of exposure and seek medical formulated as a white, oil-in-water emulsion. In addition the amount of opioid and/or a-2 agonist premedication will Rapid single or repeat bolus administration may cause or sedative effect of propofol and result in more pronounced the stability of the product has been compromised. Slight attention. Respiratory depression should be treated by to the active component, propofol, the formulation also influence the response of the patient to an induction dose of undesirable cardiorespiratory depression including changes in systolic, diastolic and mean arterial blood pressures. creaming, which should disappear after shaking, may be artificial ventilation and oxygen. Distributed by: contains soybean oil (100 mg/mL), glycerol (22.5 mg/mL), egg visible upon prolonged standing. Do not use if particulate propofol. hypotension, apnea and oxygen desaturation. 5. Breeding animals: The use of propofol in pregnant and Zoetis Inc. Hypersensitivity reactions to propofol, including anaphylaxis, lecithin (12 mg/mL), and oleic acid (0.6 mg/mL) with sodium matter and discoloration are present. In the presence of premedication, the dose of propofol may breeding dogs has not been evaluated. Propofol crosses the Kalamazoo, MI 49007 When using propofol, dogs should be continuously may occur in some individuals who are also allergic to muscle hydroxide to adjust the pH. The propofol emulsion is isotonic be reduced with increasing age of the animal. The dose of placenta and, as with other general anesthetic agents, the Revised: May 2021 Propofol contains no antimicrobial preservatives. Strict monitored and facilities for the maintenance of a patent 7 and has a pH of 6.0-9.0. relaxants . aseptic techniques must always be maintained during propofol should always be titrated against the response of airway, artificial ventilation, and oxygen supplementation administration of propofol may be associated with neonatal Avoid inhalation and direct contact of this product with skin, CLINICAL PHARMACOLOGY: handling since the vehicle is capable of supporting the patient. must be immediately available. depression. eyes, and clothes. In case of contact, eyes and skin should Propofol injection is an intravenous sedative hypnotic agent the rapid growth of microorganisms. Failure to follow During induction, additional low doses of propofol, similar 6. Neonates: Propofol has not been evaluated in dogs less 339 072 SIDE EFFECTS: be liberally flushed with water for 15 minutes. Consult a for use in the induction and maintenance of anesthesia. aseptic handling procedures may result in microbial to those used for maintenance with propofol, may be than 10 weeks of age. The primary side effect of propofol is respiratory depression physician if irritation persists. Intravenous injection of propofol in the dog is followed by contamination causing fever, infection/sepsis, and/or administered to facilitate intubation or the transition to as evidenced by tachypnea and apnea. Tachypnea and apnea 7. Compromised or debilitated dogs: Doses may need extensive metabolism of propofol in the liver to inactive other life-threatening illness. Do not use if contamination CONTACT INFORMATION: inhalant maintenance anesthesia. were observed in 43 and 26% of the cases in the clinical trial, adjustment for geriatric or debilitated patients. The conjugates which are excreted in the urine. Elimination is suspected. administration of propofol to patients with renal failure and/ To report suspected adverse events, for technical assistance from the central compartment occurs rapidly, with an initial MAINTENANCE OF GENERAL ANESTHESIA: respectively. All cases of apnea resumed normal breathing
Load more

Recommended publications
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Safe Injection Practices for Administration of Propofol
    Safe Injection Practices for Administration of Propofol CECIL A. KING, MS, RN; MARY OGG, MSN, RN, CNOR ABSTRACT Sepsis and postoperative infection can occur as a result of unsafe practices in the administration of propofol and other injectable medications. Investigations of infec- tion outbreaks have revealed the causes to be related to bacterial growth in or contamination of propofol and unsafe medication practices, including reuse of syringes on multiple patients, use of single-use medication vials for multiple pa- tients, and failure to practice aseptic technique and adhere to infection control practices. Surveys conducted by AORN and other researchers have provided addi- tional information on perioperative practices related to injectable medications. In 2009, the US Food and Drug Administration and the Centers for Disease Control and Prevention convened a group of clinicians to gain a better understanding of the issues related to infection outbreaks and injectable medications. The meeting participants proposed collecting data to persuade clinicians to adopt new practices, developing guiding principles for propofol use, and describing propofol-specific, site-specific, and practitioner-specific injection techniques. AORN provides resources to help perioperative nurses reduce the incidence of postoperative infection related to med- ication administration. AORN J 95 (March 2012) 365-372. © AORN, Inc, 2012. doi: 10.1016/j.aorn.2011.06.009 Key words: sterile injectable medications, propofol, sepsis, safe injection prac- tices, safe medication
    [Show full text]
  • Statement on Safe Use of Propofol 2019
    Statement on Safe Use of Propofol Committee of Origin: Ambulatory Surgical Care (Approved by the ASA House of Delegates on October 27, 2004, and amended on October 23, 2019) Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. The Society believes that the involvement of an anesthesiologist in the care of every patient undergoing anesthesia is optimal. However, when this is not possible, non-anesthesia personnel who administer propofol should be qualified to rescue* patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.** • The physician responsible for the use of sedation/anesthesia should have the education and training to manage the potential medical complications of sedation/anesthesia. The physician should be proficient in airway management, have advanced life support skills appropriate for the patient population, and understand the pharmacology of the drugs used. The physician should be physically present throughout the sedation and remain immediately available until the patient is medically discharged from the post procedure recovery area. • The practitioner administering propofol for sedation/anesthesia should, at a minimum, have the education and training to identify and manage the airway and cardiovascular changes which occur in a patient who enters a state of general anesthesia, as well as the ability to assist in the management of complications.
    [Show full text]
  • Aminobutyric Acid Type a and Glycine Receptors Influences Their Sensitivity to Propofol
    PERIOPERATIVE MEDICINE A Single Phenylalanine Residue in the Main Intracellular Loop of ␣1 ␥-Aminobutyric Acid Type A and Glycine Receptors Influences Their Sensitivity to Propofol Gustavo Moraga-Cid, Ph.D.,* Gonzalo E. Yevenes, Ph.D.,* Gu¨ nther Schmalzing, M.D.,† Robert W. Peoples, Ph.D.,‡ Luis G. Aguayo, Ph.D.§ Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/115/3/464/254366/0000542-201109000-00010.pdf by guest on 02 October 2021 ABSTRACT What We Already Know about This Topic • Propofol positively modulates receptors for the inhibitory Background: The intravenous anesthetic propofol acts as a transmitters ␥-aminobutyric acid type A (GABA) and glycine, positive allosteric modulator of glycine (GlyRs) and ␥-ami- but the molecular mechanisms involved are unclear nobutyric acid type A (GABAARs) receptors. Although the role of transmembrane residues is recognized, little is known about the involvement of other regions in the modulatory What This Article Tells Us That Is New effects of propofol. Therefore, the influence of the large in- • A single homologous residue in the large M3-M4 intracellular tracellular loop in propofol sensitivity of both receptors was ␣ loops of the 1 subunits of GABAA and glycine receptors mod- explored. ulates the action of propofol but not of other general anesthetics ␣ ␣ ␤ Methods: The large intracellular loop of 1 GlyRs and 1 2 GABAARs was screened using alanine replacement. Sensitiv- ity to propofol was studied using patch-clamp recording in 80 Ϯ 23%). Remarkably, propofol-hyposensitive mutant re- HEK293 cells transiently transfected with wild type or mu- ceptors retained their sensitivity to other allosteric modula- tant receptors.
    [Show full text]
  • Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor Glun2a (NR2A) Subunit AK Salous Marquette University
    Marquette University e-Publications@Marquette Biomedical Sciences Faculty Research and Biomedical Sciences, Department of Publications 11-1-2009 Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit AK Salous Marquette University H Ren Marquette University KA Lamb Marquette University Xiang-Qun Hu Marquette University, [email protected] RH Lipsky George Mason University See next page for additional authors Accepted version. British Journal of Pharmacology, Vol. 158, No. 5 (November 2009): 1395–1404. DOI. © 2009 Wiley. Used with permission. This is the peer reviewed version of the following article: "Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit," which has been published in final form here: DOI. This article may be used for non- commercial purposes in accordance With Wiley Terms and Conditions for self-archiving. Authors AK Salous, H Ren, KA Lamb, Xiang-Qun Hu, RH Lipsky, and Robert W. Peoples This article is available at e-Publications@Marquette: https://epublications.marquette.edu/biomedsci_fac/95 NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation at the bottom of the page. Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit AK Salous Department of Biomedical Sciences, Marquette University Milwaukee, WI H. Ren Department of Biomedical Sciences, Marquette University Milwaukee, WI KA Lamb Department of Biomedical Sciences, Marquette University Milwaukee, WI X-Q Hu Department of Biomedical Sciences, Marquette University Milwaukee, WI RH Lipsky Department of Neuroscience, INOVA Fairfax Hospital Falls Church, VA Krasnow Institute for Advanced Study, George Mason University Fairfax, VA RW Peoples Department of Biomedical Sciences, Marquette University Milwaukee, WI British Journal of Pharmacology, Vol.
    [Show full text]
  • Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery a Randomized Controlled Trial Robert S
    Anesthesiology 2002; 97:585–91 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Robert S. Kong, F.R.C.A.,* John Butterworth, M.D.,† Wynne Aveling, F.R.C.A.,‡ David A. Stump, M.D.,† Michael J. G. Harrison, F.R.C.P.,§ John Hammon, M.D.,ʈ Jan Stygall, M.Sc.,# Kashemi D. Rorie, Ph.D.,** Stanton P. Newman, D.Phil.†† Background: The neuroprotective property of clomethiazole THE efficacy of coronary artery bypass surgery in the has been demonstrated in several animal models of global and relief of angina and in some circumstances in enhancing Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/3/585/335909/0000542-200209000-00011.pdf by guest on 29 September 2021 focal brain ischemia. In this study the authors investigated the life expectation is now accepted. It is a tribute to the low effect of clomethiazole on cerebral outcome in patients under- mortality of the procedure that interest is now focused going coronary artery bypass surgery. Methods: Two hundred forty-five patients scheduled for on the neurologic and neuropsychological complica- 1–3 coronary artery bypass surgery were recruited at two centers tions. Adverse neurologic outcomes have been found and prospectively randomized to clomethiazole edisilate to occur in 2–6% of patients and neuropsychological (0.8%), 225 ml (1.8 mg) loading dose followed by a maintenance deficits in 10–30%.4–6 These complications are consid- dose of 100 ml/h (0.8 mg/h) during surgery, or 0.9% NaCl ered to be ischemic in nature, being a consequence of (placebo) in a double-blind trial.
    [Show full text]
  • Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Common Mechanism S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/21/mol.117.108290.DC1 1521-0111/91/6/620–629$25.00 https://doi.org/10.1124/mol.117.108290 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:620–629, June 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely through a Common Mechanism s Anita Luethy, James D. Boghosian, Rithu Srikantha, and Joseph F. Cotten Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (A.L., J.D.B., and J.F.C.); Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.); Carver College of Medicine, University of Iowa, Iowa City, Iowa (R.S.) Received January 7, 2017; accepted March 20, 2017 Downloaded from ABSTRACT The TWIK-related acid-sensitive potassium channel 3 (TASK-3; hydrate (165% [161–176]) . 2,2-dichloro- . 2-chloro 2,2,2- KCNK9) tandem pore potassium channel function is activated by trifluoroethanol . ethanol. Similarly, carbon tetrabromide (296% halogenated anesthetics through binding at a putative anesthetic- [245–346]), carbon tetrachloride (180% [163–196]), and 1,1,1,3,3,3- binding cavity. To understand the pharmacologic requirements for hexafluoropropanol (200% [194–206]) activate TASK-3, whereas molpharm.aspetjournals.org TASK-3 activation, we studied the concentration–response of the larger carbon tetraiodide and a-chloralose inhibit. Clinical TASK-3 to several anesthetics (isoflurane, desflurane, sevoflurane, agents activate TASK-3 with the following rank order efficacy: halothane, a-chloralose, 2,2,2-trichloroethanol [TCE], and chloral halothane (207% [202–212]) .
    [Show full text]
  • Pharmacokinetics of Propofol Administered by Target- Controlled Infusion to Alcoholic Patients Frédérique S
    Anesthesiology 2003; 99:576–85 © 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Pharmacokinetics of Propofol Administered by Target- controlled Infusion to Alcoholic Patients Frédérique S. Servin, M.D.,* Bernard Bougeois, M.D.,* Roberto Gomeni, Ph.D.,† France Mentré, M.D., Ph.D.,‡ Robert Farinotti, Ph.D.,§ Jean-Marie Desmonts, M.D.ʈ Background: Chronic alcoholic patients are frequently pre- require larger doses of “anesthetic agents,” even in the sented for anesthesia and surgery. These patients require absence of withdrawal symptoms. Although it is com- higher doses of propofol than control patients for induction of monly recommended that the dose of thiopental should anesthesia, but whether this is because of changes in pharma- cokinetics or pharmacodynamics is not known. This study was be increased in alcoholic patients, no pharmacokinetic designed to investigate the influence of chronic ethanol intake or pharmacodynamic changes could be demonstrated in Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/99/3/576/337574/0000542-200309000-00012.pdf by guest on 26 September 2021 on propofol pharmacokinetics. chronic alcoholic patients.2 Moreover, unnecessarily Methods: Fifteen chronic alcoholic and 15 control patients, high doses may be deleterious in this population in receiving propofol by target-controlled infusion for otolaryn- whom alcohol-related cardiac disease is frequent.3 In gologic surgery, were studied. Blood propofol concentrations 4 were measured at regular intervals during and after the propo- addition to sporadic case reports, a prospective study fol infusion. Nonlinear mixed-effects population models (NON- has shown that the induction dose of propofol was MEM) examining the influence of alcoholism were constructed.
    [Show full text]
  • A New Pharmacokinetic Model of Propofol for Japanese Patients
    Open Journal of Anesthesiology, 2019, 9, 179-188 https://www.scirp.org/journal/ojanes ISSN Online: 2164-5558 ISSN Print: 2164-5531 A New Pharmacokinetic Model of Propofol for Japanese Patients Masahito Omote, Shunsuke Tachibana, Yasuyuki Tokinaga* , Michiaki Yamakage Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan How to cite this paper: Omote, M., Ta- Abstract chibana, S., Tokinaga, Y. and Yamakage, M. (2019) A New Pharmacokinetic Model Target-controlled infusion (TCI) of propofol is used for general anesthesia. of Propofol for Japanese Patients. Open However, the only pharmacokinetic parameter commercially used for Japa- Journal of Anesthesiology, 9, 179-188. nese patients is weight, and pharmacokinetic models are based on European https://doi.org/10.4236/ojanes.2019.99017 physical attributes. Drug metabolism also differs in races. This study aimed to Received: August 25, 2019 identify optimal continuous doses of propofol for Japanese patients and to Accepted: September 16, 2019 create a simulated pharmacokinetic (PK) model. Thirty Japanese patients Published: September 19, 2019 were enrolled. Patients received a constant infusion of 9 mg/kg/h of propo- Copyright © 2019 by author(s) and fol. Arterial blood samples were collected and the time course of plasma Scientific Research Publishing Inc. propofol concentrations was modeled using the nonlinear mixed effects This work is licensed under the Creative model (NONMEM) three-compartmental PK model. We validated the model Commons Attribution International License (CC BY 4.0). by intravenously injecting 10 patients with a TCI driver system programmed http://creativecommons.org/licenses/by/4.0/ with the NONMEM model. Our model’s performance was evaluated using Open Access the median prediction error (MDPE), median absolute prediction error (MDAPE), and Wobble.
    [Show full text]
  • Potentiating Action of Propofol at GABAA Receptors of Retinal Bipolar Cells
    Visual Neurophysiology Potentiating Action of Propofol at GABAA Receptors of Retinal Bipolar Cells Lan Yue,1,2 An Xie,1 Karol S. Bruzik,3 Bente Frølund,4 Haohua Qian,1,5 and David R. Pepperberg1,2 PURPOSE. Propofol (2,6-diisopropyl phenol), a widely used sys- etinal bipolar cells have GABAA and GABAC receptors, which ␥ temic anesthetic, is known to potentiate GABAA receptor ac- Rare pentameric, ligand-gated ion channels activated by -ami- tivity in a number of CNS neurons and to produce changes in nobutyric acid (GABA). GABAA and GABAC receptors mediate fast electroretinographically recorded responses of the retina. inhibitory signaling in bipolar cells of the retina1–3 (see Ref. 4 for However, little is known about propofol’s effects on specific review). Electrophysiological and immunocytochemical data indi- retinal neurons. The authors investigated the action of propo- cate that GABAA and GABAC receptors on bipolar cells are local- fol on GABA-elicited membrane current responses of retinal ized primarily at the axon terminals, postsynaptic to amacrine 5–7 ␣ ␣ bipolar cells, which have both GABA and GABA receptors. cells. Furthermore, expression of GABAA receptor 1, 3, A C ␤ ␥ ␳ ␳ 2/3, and 2 subunits and GABAC receptor 1 and 2 subunits in METHODS. Single, enzymatically dissociated bipolar cells ob- rod bipolar cells has been reported.8–11 However, the specific tained from rat retina were treated with propofol delivered by subunit compositions of these receptors of bipolar cells are as yet brief application in combination with GABA or other pharma- unknown. cologic agents or as a component of the superfusing medium.
    [Show full text]
  • Current Methods of Sedation in Dental Patients - a Systematic Review of the Literature
    Med Oral Patol Oral Cir Bucal. 2016 Sep 1;21 (5):e579-86. Conscious sedation in dentistry Journal section: Medically compromised patients in Dentistry doi:10.4317/medoral.20981 Publication Types: Review http://dx.doi.org/doi:10.4317/medoral.20981 Current methods of sedation in dental patients - a systematic review of the literature Jose-Ramón Corcuera-Flores 1, Javier Silvestre-Rangil 2, Antonio Cutando-Soriano 3, Julián López-Jiménez 4 1 PhD, DDS, Associate Professor. Special Care in Dentistry, School of Dentistry, University of Seville, Spain 2 PhD, DDS, Associate Professor. Special Care in Dentistry, School of Dentistry, University of Valencia, Spain 3 PhD, MD, DDS, Professor. Special Care in Dentistry, School of Dentistry, University of Granada, Spain 4 PhD, MD, DDS. “Nen Deu” Private Practice Hospital, Barcelona, Spain Correspondence: School of Dentistry C/Avicena s/n Corcuera-Flores JR, Silvestre-Rangil J, Cutando-Soriano A, López-Ji- 41009 Seville, Spain ménez J. Current methods of sedation in dental patients - a systematic [email protected] review of the literature. Med Oral Patol Oral Cir Bucal. 2016 Sep 1;21 (5):e579-86. http://www.medicinaoral.com/medoralfree01/v21i5/medoralv21i5p579.pdf Received: 31/07/2015 Article Number: 20981 http://www.medicinaoral.com/ Accepted: 16/03/2016 © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946 eMail: [email protected] Indexed in: Science Citation Index Expanded Journal Citation Reports Index Medicus, MEDLINE, PubMed Scopus, Embase and Emcare Indice Médico Español Abstract Objective: The main objective of this systematic literature review is to identify the safest and most effective seda- tive drugs so as to ensure successful sedation with as few complications as possible.
    [Show full text]
  • Sedation in Fmri : an Unsolved Challenge
    Sedation in fMRI : An unsolved challenge Byron Bernal *, MD Nolan Altman**, MD There are many medications that can be utilized to sedate children undergoing fMR examinations. The most frequently used drugs are chloral hydrate, thiopenthal, phenobarbital, propofol, and fentanyl. These medications have some secondary effects on the electrical and metabolic activity of the cortex, cerebral blood flow(CBF), cerebral blood volume(CBV), and tissue oxygen extraction. These effects are of no concern in regular MRI (Magnetic Resonance Imaging), however, may have a significant contribution in fMR performed in the sedated child. Since fMRI is based on the hemodynamic and metabolic response of the brain to a given stimulus the selection of the sedation medication seems crucial. The following reviews the current knowledge regarding the relation of these drugs to these physiological parameters. Chloral Hydrate.- Chloral hydrate (CH) does not reduce brain cortex activity. This is demonstrated on EEG where it is widely used. Thoresen M and Henriksen O (1997) did not find changes on the EEGs in 9 out of 13 children with epileptic seizures, before and after CH was administered. We do not know of any reported studies relating CBF, CBV, or cerebral regional metabolism changes, and CH in humans. Propofol.- Propofol has been used as a sedative in children undergoing EEGs. Low propofol doses (0.5- 1 mg/kg) show an increase in the number of beta-waves and a significant reduction of alpha- and theta- waves . Larger doses of propofol (total dose of 2-2.5 mg/kg), the number of beta-waves decreased and delta-waves appeared.
    [Show full text]